22:55 , May 11, 2018 |  BioCentury  |  Strategy

Takeda hits the gas

Takeda Pharmaceutical Co. Ltd.’s proposed acquisition of Shire plc is an acceleration of -- not a departure from -- CEO Christophe Weber’s stated strategy to build a top-tier global pharma, according to management. On May...
19:57 , May 3, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: April 2018

New Therapeutic Targets and Biomarkers: April 2018...
21:46 , Apr 25, 2018 |  BC Innovations  |  Translation in Brief

Prostate prognosis

A Dana-Farber Cancer Institute team has uncovered previously unreported associations between prostate cancer and low-frequency mutations in 79 genes that could serve as prognostic markers for metastatic disease. The results, published this month in...
01:23 , Mar 31, 2018 |  BioCentury  |  Strategy

Refashioning Takeda

Takeda Pharmaceutical Co. Ltd.’s potential acquisition of Shire plc appears to be timed to take advantage of the chance to acquire products and a global footprint on the cheap. The combination would create a global...
19:16 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

Galapagos reports Phase Ib data for GLPG1972 in OA

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) reported top-line data from a Phase Ib trial in 30 patients ages 50-75 with knee and/or hip osteoarthritis (OA) showing that three dose levels of once-daily oral GLPG1972 for four weeks...
19:42 , Oct 3, 2017 |  BC Innovations  |  Distillery Therapeutics

Musculoskeletal

INDICATION: Musculoskeletal Mouse studies suggest activating ADAMTS1 could help treat muscle injury. In a mouse model of muscle injury, levels of ADAMTS1 were higher in the injured muscle than in the contralateral uninjured muscle. Also...
18:01 , Sep 1, 2017 |  BC Week In Review  |  Company News

Servier gets rights to Galapagos' OA candidate

In July, Servier (Neuilly-sur-Seine, France) said it exercised its option for worldwide commercialization rights, excluding the U.S., to GLPG1972 (S201086) from Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG). Galapagos retains U.S. commercialization rights. Galapagos will receive a €6...
04:35 , Jan 27, 2017 |  BC Week In Review  |  Clinical News

IdeS: Ph II discontinued

Hansa discontinued an open-label, U.K. Phase II trial evaluating a single IV dose of IdeS after preliminary data from 2 asymptomatic patients with acquired TTP showed a "non-favorable" risk-benefit profile. The company said that while...
07:00 , Oct 17, 2016 |  BC Week In Review  |  Clinical News

IdeS: Phase II started

Hansa began an open-label, U.K. Phase II trial to evaluate single doses of 0.25 and 0.5 mg/kg IV IdeS in up to 6 patients with acquired TTP and low ADAMTS13 activity who are asymptomatic. Hansa...
07:00 , Sep 10, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: ADAM metallopeptidase with thrombospondin type 1 motif 13 (ADAMTS13)

Hematology INDICATION: Thrombocytopenia In vitro studies suggest a modified form of ADAMTS13 could help treat thrombotic thrombocytopenic purpura ( TTP ). Autoantibodies from TTP patients inhibit ADAMTS13-mediated cleavage of von Willebrand factor (vWF) by an...